Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Niraparib in Metastatic Castration-Resistant Prostate Cancer with DNA-Repair Anomalies
2016-002057-38Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of niraparib in metastatic castration-resistant prostate cancer (mCRPC) (2 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: Objective response rate in soft tissue without bone progression. Started Aug 2016; status: completed.
02
Drugs
niraparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2016-002057-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002057-38.